Final Results from Phase 2 Open-Label Extension Study of OXLUMO® (lumasiran) Presented at ERA Congress

Final Results from Phase 2 Open-Label Extension Study of OXLUMO® (lumasiran) Presented at ERA Congress

New 54-month results from the Phase 2 open-label extension study evaluating long-term treatment with OXLUMO® (lumasiran) in patients with primary hyperoxaluria type 1 were presented at the 61st European Renal Association (ERA) Congress.

Frishberg, et al. “Long-term Treatment with Lumasiran: Final Results from the Phase 2 Open-Label Extension Study”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.